Expert retina and uveitis specialists will help support the growth and innovation of ANI’s ophthalmology and retina franchise for a meaningful impact on patientsPRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that it has established The FutureVision Advisory Council to help guide the strategic advancement of its ophthalmology and retina franchise within the Company’s Rare Disease business. This steering committee includes s ...

Core Insights - ANI Pharmaceuticals, Inc. announced the presentation of results from the NEW DAY clinical trial of ILUVIEN® for diabetic macular edema at the American Academy of Ophthalmology 2025 Meeting [1][2] Group 1: Clinical Trial Results - The NEW DAY trial results will be presented in a late-breaking oral presentation titled "A Randomized, Active-Controlled Trial of Fluocinolone Acetonide 0.19mg Intravitreal Implant for Diabetic Macular Edema: The NEW DAY Study" [2] - The presentation is scheduled for October 17, 2025, at 4:39 pm ET during Retina Subspecialty Day 2025 [2] - Previous presentations of the NEW DAY results have occurred at various medical meetings earlier this year [3] Group 2: Product Information - ILUVIEN is indicated for the treatment of diabetic macular edema in patients previously treated with corticosteroids without a significant rise in intraocular pressure [3] - The product is a corticosteroid delivered via an intravitreal implant [1] Group 3: Company Overview - ANI Pharmaceuticals is focused on developing, manufacturing, and commercializing innovative therapeutics across various therapeutic areas, including ophthalmology [10] - The company aims for sustainable growth through its Rare Disease, Generics, and Brands business segments [10]